Note: Descriptions are shown in the official language in which they were submitted.
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
PYRIDINE DERIVATIVES AS INHIBITORS OF P38
TECHNICAL FIELD OF INVENTION
The present invention relates to inhibitors of
p38, a mammalian protein kinase involved in cell
proliferation, cell death and response to extracellular
stimuli. The invention also relates to methods for
producing these inhibitors. The invention also provides
pharmaceutical compositions comprising the inhibitors of
the invention and methods of utilizing those compositions
in the treatment and prevention of various disorders.
BACKGROUND OF THE INVENTION
Protein kinases are involved in various
cellular responses to extracellular signals. Recently, a
family of mitogen-activated protein kinases (MAPK) has
been discovered. Members of this family are Ser/Thr
kinases that activate their substrates by phosphorylation
[B. Stein et al., Ann. Rep. Med. Chem., 31, pp. 289-98
(1996)]. MAPKs are themselves activated by a variety of
signals including growth factors, cytokines, UV
radiation, and stress-inducing agents.
One particularly interesting MAPK is p38. p38,
also known as cytokine suppressive anti-inflammatory drug
binding protein (CSBP) and RK, was isolated from murine
pre-B cells that were transfected with the
lipopolysaccharide (LPS) receptor, CD14, and induced with
LPS. p38 has since been isolated and sequenced, as has
the cDNA encoding it in humans and mouse. Activation of
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-2-
p38 has been observed in cells stimulated by stress, such
as treatment of lipopolysaccharides (LPS), W,
anisomycin, or osmotic shock, and by cytokines, such as
IL-1 and TNF.
Inhibition of p38 kinase leads to a blockade on
the production of both IL-1 and TNF. IL-1 and TNF
stimulate the production of other proinflammatory
cytokines such as IL-6 and IL-8 and have been implicated
in acute and chronic inflammatory diseases and in post-
menopausal osteoporosis [R. B. Kimble et al.,
Endocrinol., 136, pp. 3054-61 (1995)].
Based upon this finding, it is believed that
p38, along with other MA.PKs, have a role in mediating
cellular response to inflammatory stimuli, such as
leukocyte accumulation, macrophage/monocyte activation,
tissue resorption, fever, acute phase responses and
neutrophilia. In addition, MAPKs, such as p38, have been
implicated in cancer, thrombin-induced platelet
aggregation, immunodeficiency disorders, autoimmune
diseases, cell death, allergies, osteoporosis and
neurodegenerative disorders. Inhibitors of p38 have also
been implicated in the area of pain management through
inhibition of prostaglandin endoperoxide synthase-2
induction. Other diseases associated with Il-1, IL-6,
IL-8 or TNF overproduction are set forth in WO 96/21654.
Others have already begun trying to develop
drugs that specifically inhibit MAPKs. For example, PCT
publication WO 95/31451 describes pyrazole compounds that
inhibit MAPKs, and, in particular, p38. However, the
efficacy of these inhibitors in vi vo is still being
investigated.
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-3-
Other p38 inhibitors have been produced,
including those described in WO 98/27098, WO 99/00357, WO
99/10291, WO 99/58502, WO 99/64400, WO 00/17175 and WO
00/17204.
Accordingly, there is still a great need to
develop other potent inhibitors of p38, including p38-
specific inhibitors, that are useful in treating various
conditions associated with p38 activation.
Another protein kinase that is involved in
cellular responses to extracellular signals is ZAP70.
When the T cell receptor (TCR) in T cells is triggered by
binding an antigen, it in turn activates ZAP70. ZAP70
acts to couple the TCR to a number of essential
signalling pathways that are required for T cell
differentiation and proliferation.
Given ZAP70's role in T cell signalling, ZAP70
may have a role in T cell mediated diseases. Such
diseases include, without limitation, transplantation,
autoimune disease, e.g., RA, systemic lupus erythematosus
(SLE), psoriasis, Sjogren's Syndrome, thyroiditis,
pulmonary fibrosis, bronchiolitis obliterans, hemolytic
anemia and Wegener's granulomatosis, cancer, including
leukemia and lymphoma, multiple sclerosis, graft versus
host disease, and Kawasaki syndrome.
Accordingly, there is a great need to develop
inhibitors of ZAP70 that are useful in treating various
conditions associated with ZAP70 activation.
SUMMARY OF THE INVENTION
The present invention addresses this problem by
providing compounds that demonstrate inhibition of p38
and/or ZAP70.
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-4-
These compounds have the general formula:
V~
NH
(Ia), (Ib),
O
O~~Z~NH2
~ i
R~Y~ N K 0
U~~ ~ ~ R
i
(Ic) and (Id) ,
wherein each of Q1 and Q2 are independently selected from
a phenyl or 5-6 membered aromatic heterocyclic ring
system, or a 8-10 membered bicyclic ring system
comprising aromatic carbocyclic rings, aromatic
heterocyclic rings or a combination of an aromatic
carbocyclic ring and an aromatic heterocyclic ring.
A heterocyclic ring system or a heterocyclic
ring contains 1 to 4 heteroatoms, which are independently
selected from N, 0, S, SO and 502.
The rings that make up Q1 are substituted with
1 to 4 substituents, each of which is independently
selected from halo; C1-C3 alkyl optionally substituted
with NR' 2, OR' , C02R' or CONK' 2; O- (C1-C3) -alkyl
optionally substituted with NR'2, OR', C02R' or CONR'2;
NR' 2; OCF3; CFg; N02; C02R' ; CONR' ; SR' ; S (02 ) N (R' ) 2; SCF3;
CN; N (R' ) C (0) R~; N (R' ) C (0) ORS; N (R' ) C (O) C (0) R4;
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-5-
N (R' ) S (0~) R4; N (R' ) R4; N (R4) 2; OR4; OC (0) R4; OP (0) sH2: or
N=C-N(R')2.
The rings that make up Q2 are optionally
substituted with up to 4 substituents, each of which is
independently selected from halogen; C1-C3 straight or
branched alkyl optionally substituted with R', NR'2, OR',
CO~R' , S (02) N (R' ) 2, N=C-N (R' ) 2, R3, 0-P (Os) H2, or CONK' 2; 0-
(C1-C~)-alkyl; 0-(C1-C3)-alkyl optionally substituted with
NR' ~, OR' , C02R' , S (02) N (R' ) 2, N=CR' -N (R' ) 2, R3, OP (03) H2,
or CONR' 2; NR' 2; OCF3; CF3; N02; CO~R' ; CONR' ~; R3; OR3;
NR3~; SR3; C (0) R3: C (0) N (R' ) R3; C (0) OR3: SR' ; S (0~) N (R' ) 2;
SCF3; N=CR' -N (R' ) 2: OR4; 0-C02R9; N (R' ) C (0) R9;
N (R' ) C (0) OR4; N (R' ) C (O) C (0) R9; N (R' ) S (O2) R4; N (R' ) R9;
N (R4) 2; ORS; OC (0) R9; OP (0) 3H2; K; or CN.
Each R' is independently selected from
hydrogen; (C1-C3) -alkyl; (C2-C3) -alkenyl or alkynyl;
phenyl or phenyl substituted with 1 to 3 substituents
independently selected from halo, methoxy, cyano, nitro,
amino, hydroxy, methyl or ethyl; or a 5-6 membered
heterocyclic ring system optionally substituted with 1 tc
3 substituents independently selected from halo, methoxy,
cyano, vitro, amino, hydroxy, methyl or ethyl.
Each R is independently selected from hydrogen,
-R2~ -N(R2)2~ -ORZ, SRS, -C(0)-N(R2)2~ -S(02)-N(R2)2~
-C(0)-OR2 or -C(0)R2 wherein two adjacent R are optionally
bound to one another and, together with each Y to which
they are respectively bound, form a 4-8 membered
carbocyclic or heterocyclic ring.
Each R2 is independently selected from
hydrogen; or (C1-C3)-alkyl or (C1-C3)-alkenyl, each
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
- 6-
optionally substituted with -N(R')~, -OR', SR', -O-C(0)-
N (R' ) 2, -C (0) -N (R' ) 2, -S (02) -N (R' ) 2, -C (0) -OR' , -NS02R~,
NS02R3, -C (0) N (R' ) (R3) , -NC (0) R4, -N (R' ) (R3) , -N (R' ) (R4) , -
C(0)R3, -C(0)N(R') (R4), -N(R4)2, -C(0)N=C(NH)2 or R3.
Each R3 is independently selected from 5-8
membered aromatic or non-aromatic carbocyclic or
heterocyclic ring systems each optionally substituted
with R' , R4, -C (0) R' , -C (0) R4, -C (0) OR4 or -K; or an 8-10
membered bicyclic ring system comprising aromatic
carbocyclic rings, aromatic heterocyclic rings or a
combination of an aromatic carbocyclic ring and an
aromatic heterocyclic ring each optionally substituted
with R' , R4, -C (0) R' , -C (0) R4, -C (0) OR4 or -K.
Each R4 is independently selected from R'; (Cz-
C~)-straight or branched alkyl optionally substituted
with R' , N (R' ) 2, OR' , C02R' , CON (R' ) z, S02N (R' ) ~ or
S02N(R5)z; or a 5-6 membered carbocyclic or heterocyclic
ring system optionally substituted with N(R')2, OR',
C02R' , CON (R' ) 2, SOzN (R' ) 2 Or SO2N (R5 ) 2.
Each R5 is independently selected from
hydrogen, (C1-C3)-alkyl, or (C1-C3)-alkenyl; each
optionally substituted with -N(R')~, -OR', SR', -C(O)-
N (R' ) 2, -S (02) -N (R' ) 2, -C (0) -OR' , -N-S (0~) (R' ) , -NS02R6, -
C (0) N (R' ) (R6) , -NC (0) R' , -N (R' ) (R6) , -C (0) R6, -
C (O) N=C (NH) Z or R6.
Each R6 is independently selected from 5-8
membered aromatic or non-aromatic carbocyclic or
heterocyclic ring systems each optionally substituted
with R', -C(0)R' or -C(O)OR'; or an 8-10 membered
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-
bicyclic ring system comprising aromatic carbocyclic
rings, aromatic heterocyclic rings or a combination of an
aromatic carbocyclic ring and an aromatic heterocyclic
ring each optionally substituted with R', -C(O)R' or
C(0)OR'.
R~ is selected from H, halogen, or a (C1-C3)
straight chain or branched alkyl.
Each Y is independently selected from N or C.
If either Y is N, then R or U attached to Y is a lone
pair of electrons.
Z i s CH, N, C ( OCH3 ) , C ( CH3 ) , C (NHS ) , C ( OH ) or
C (F) .
Each U is independently selected from R or J.
Each J is independently selected from a (C1-C4)
straight chain or branched alkyl derivative substituted
with T.
Each T is independently selected from either
0 (V) or N (H) (V) .
Each V is independently selected from
C(0)N=C(R)(N(R)2), wherein the two geminal R on the
nitrogen are optionally bound to one another to form a 4-
8 membered carbocyclic or heterocyclic ring.
When the two R components form a ring, it will
obvious to those skilled in the art that a terminal
hydrogen from each unfused R component will be lost. For
example, if a ring structure is_formed by binding those
two R components together, one being -CH3 and the other
being -CH2-CH3, one terminal hydrogen on each R component
(indicated in bold) will be lost. Therefore, the
resulting portion of the ring structure will have the
formula -CH2-CHI-CH2-.
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
_g-
Each K is independently selected from a (C1-C4)
straight chain or branched alkyl derivative substituted
with D, or -OP (0) (OH) 2.
Each D is independently selected from either
Rs
enantiomer of
Each M is independently selected from either 0
or NH.
Each G is independently selected from NH2, OH,
or H.
Each R8 is independently selected from H, OH,
C(0)0H, (C1-C~)-straight or branched alkyl optionally
substituted with N (R' ) ~, OR' , C02R' , CON (R' ) 2, or
S02N (R5) 2; or a 5-6 membered carbocyclic, heterocyclic or
heteroaryl ring system optionally substituted with
N (R' ) ~, OR' , CO~R' , CON (R' ) 2, or S02N (R5 ) 2 . When G forms a
ring with R8, it will be obvious to those skilled in the
art that a terminal hydrogen from the unfused G and Re
component will be lost. For example, if a ring structure
is formed by binding the G and R8 components together,
one being -NH2 and the other being -CH2-CH2-CH2-CH3, one
terminal hydrogen on each R component (indicated in bold)
will be lost. Therefore, the resulting portion of the
ring structure will have the formula -NH-CHZ-CH2-CH2-CH2-.
In another embodiment, the invention provides
pharmaceutical compositions comprising the p38 and/or
ZAP70 inhibitors of this invention. These compositions
may be utilized in methods for treating or preventing a
variety of p38-mediated disorders, such as cancer,
inflammatory diseases, autoimmune diseases, destructive
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-9-
bone disorders, proliferative disorders, infectious
diseases, viral diseases and neurodegenerative diseases
or ZAP70-mediated disorders, including transplantation,
autoimune disease, cancer, multiple sclerosis, graft
versus host disease, and Kawasaki syndrome. These
compositions are also useful in methods for preventing
cell death and hyperplasia and therefore may be used to
treat or prevent reperfusion/ischemia in stroke, heart
attacks, and organ hypoxia. The compositions are also
useful in methods for preventing thrombin-induced
platelet aggregation. Each of these above-described
methods is also part of the present invention.
DETAINED DESCRIPTION OF THE INVENTION
These compounds have the general formula:
1 ~ ~1
V
NHS / /
J J
Q2 Q2
(Ia), (Ib),
O
Q1~Z~NH2
R~Y~ N K O
U~l~ ~ ~ R H
i
(IC) and (Id) ,
wherein each of Q1 and Q2 are independently selected from
a phenyl or 5-6 membered aromatic heterocyclic ring
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-10-
system, or a 8-10 membered bicyclic ring system
comprising aromatic carbocyclic rings, aromatic
heterocyclic rings or a combination of an aromatic
carbocyclic ring and an aromatic heterocyclic ring.
The rings that make up Q1 are substituted with
1 to 4 substituents, each of which is independently
selected from halo; C1-C3 alkyl optionally substituted
with NR' z, OR' , COzR' or CONR' z; O- (C1-C3) -alkyl
optionally substituted with NR'z, OR', COzR' or CONR'z;
NR' z; OCF3; CF3; NOz; COzR' ; CONR' ; SR' ; S (02 ) N (R' ) z; SCF3;
CN; N(R')C(O)R4; N(R')C(O)OR4; N(R')C(O)C(O)R9;
N (R' ) S (02) Rø; N (R' ) R~; N (R4) ~; OR4; OC (0) R4; OP (0) 3H2; or
N=C-N(R')a.
The rings that make up Qz are optionally
substituted with up to 4 substituents, each of which is
independently selected from halogen; C1-C3 straight or
branched alkyl optionally substituted with R', NR'z, OR',
C02R' , S (Oz) N (R' ) z, N=C-N (R' ) 2, R3, 0-P (03) H2, or CONR' z; O-
(C1-C3) -alkyl; 0- (C1-C3) -alkyl optionally substituted with
NR' z, OR' , COzR' , S (Oz ) N (R' ) z, N=CR' -N (R' ) 2, R3, OP (03) H~,
or CONR' z; NR' z; OCF3; CF3; NOz; COzR' ; CONR' 2; R3; OR3;
NR32; SR3; C (0) R3; C (0) N (R' ) R3; C (0) OR3; SR' ; S (Oz) N (R' ) z %
SCF3; N=CR' -N (R' ) ~; OR9; 0-C02R9; N (R' ) C (0) R9;
N (R' ) C (0) ORq; N (R' ) C (0) C (0) R9; N (R' ) S (02) R4; N (R' ) R4;
N (Rø) a; ORS; OC (0) R4; OP (0) 3H2; K; or CN.
Each R' is independently selected from
hydrogen; (C1-C3) -alkyl; (Cz-C3) -alkenyl or alkynyl;
phenyl or phenyl substituted with 1 to 3 substituents
independently selected from halo, methoxy, cyano, nitro,
amino, hydroxy, methyl or ethyl; or a 5-6 membered
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-11-
heterocyclic ring system optionally substituted with 1 to
3 substituents independently selected from halo, methoxy,
cyano, nitro, amino, hydroxy, methyl or ethyl.
Each R is independently selected from hydrogen,
-R2, -N (R~ ) 2r -0R2, SR2, -C (0) -N (R2) z. -S (02) -N (R2) 2r
-C (O) -OR2 or -C (0) R2 wherein two adjacent R are optionally
bound to one another and, together with each Y to which
they are respectively bound, form a 4-8 membered
carbocyclic or heterocyclic ring.
Each R~ is independently selected from
hydrogen; or (C~-C3)-alkyl or (C1-C3)-alkenyl, each
optionally substituted with -N(R')2, -OR', SR', -0-C(0)-
N (R' ) 2, -C (O) -N (R' ) ~, -S (02) -N (R' ) ~, -C (0) -OR' , -NSO~R~, -
NSOZR3, -C {0) N (R' ) {R3) , -NC (O) R4, -N {R' ) (R3) , -N (R' ) (R4) , -
C (0) R3, -C (0) N {R' ) (R4) , -N (R4) ~, -C (0) N=C (NH) 2 or R3.
Each R3 is independently selected from 5-8
membered aromatic or non-aromatic carbocyclic or
heterocyclic ring systems each optionally substituted
with R' , R4, -C (0) R' , -C (0) R4, -C (0) OR4 or -K; or an 8-10
membered bicyclic ring system comprising aromatic
carbocyclic rings, aromatic heterocyclic rings or a
combination of an aromatic carbocyclic ring and an
aromatic heterocyclic ring each optionally substituted
With R' , R~, -C (0) R' , -C (0) R4, -C (0) OR4 or -K.
Each R4 is independently selected from R'; (C1-
C~)-straight or branched alkyl optionally substituted
with R' , N (R' ) 2, OR' , COzR' , CON (R' ) 2, SON (R' ) 2 or
S02N(R5)~; or a 5-6 membered carbocyclic or heterocyclic
ring system optionally substituted with N(R')~, OR',
C02R' , CON (R' ) 2, S02N (R' ) z or S02N (R5 ) z
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-12
Each R5 is independently selected from
hydrogen, (C1-C3) -alkyl, or (C1-C3) -alkenyl; each
optionally substituted with -N(R')2, -OR', SR', -C(0)-
N (R' ) 2, -S (02) -N (R' ) 2, -C (0) -OR' , -N-S (02) (R' ) , -NS02R6, -
C (0) N (R' ) (R6) , -NC (0) R' , -N (R' ) (R6) , -C (0) R6, -
C (O) N=C (NH) 2 or R6 .
Each R6 is independently selected from 5-8
membered aromatic or non-aromatic carbocyclic or
heterocyclic ring systems each optionally substituted
with R' , -C (0) R' or -C (0) OR' ; or an 8-10 membered
bicyclic ring system comprising aromatic carbocyclic
rings, aromatic heterocyclic rings or a combination of an
aromatic carbocyclic ring and an aromatic heterocyclic
ring each optionally substituted with R', -C(O)R' or
C(O)OR'.
R~ is selected from H, halogen, or a (C1-C3)
straight chain or branched alkyl.
Each Y is independently selected from N or C.
If either Y is N, then R or U attached to Y is a lone
pair of electrons.
Z is CH, N, C (OCH3) , C (CH3) , C (NHS) , C (OH) or
C (F) .
Each U is independently selected from R or J.
Each J is independently selected from a (C1-C4)
straight chain or branched alkyl derivative substituted
with T.
Each T is independently selected from either
0 (V) or N (H) (V) .
Each V is independently selected from
C(O)N=C(R)(N(R)2), wherein the two geminal R on the
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-13-
nitrogen are optionally bound to one another to form a 4-
8 membered carbocyclic or heterocyclic ring.
When the two R components form a ring, it will
obvious to those skilled in the art that a terminal
hydrogen from each unfused R component will be lost. For
example, if a ring structure is formed by binding those
two R components together, one being -CH3 and the other
being -CH2-CH3, one terminal hydrogen on each R component
(indicated in bold) will be lost. Therefore, the
resulting portion of the ring structure will have the
formula -CHI-CH2-CH2-.
Each K is independently selected from a (C1-C4)
straight chain or branched alkyl derivative substituted
with D, or -OP (0) (OH) 2.
Each D is independently selected from either
vt ~,.,
enantiomer of I~~I ~ .
Each M is independently selected from either 0
or NH.
Each G is independently selected from NHz, OH,
or H.
Each R8 is independently selected from H, OH,
C(0)OH, (C1-C~)-straight or branched alkyl optionally
substituted with N (R' ) 2, OR' , CO~R' , CON (R' ) ~, or
SON (R5) 2; or a 5-6 membered carbocyclic, heterocyclic or
heteroaryl ring system optionally substituted with
N (R' ) Z, OR' , CO~R' , CON (R' ) z, or S02N (R5) 2 . When G forms a
ring with R8, it will be obvious to those skilled in the
art that a terminal hydrogen from the unfused G and R8
component will be lost. For example, if a ring structure
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-14-
is formed by binding the G and R8 components together,
one being -NH2 and the other being -CH2-CHI-CHI-CH3, one
terminal hydrogen on each R component (indicated in bold)
will be lost. Therefore, the resulting portion of the
ring structure will have the formula -NH-CH2-CH2-CH2-CH2-.
A heterocyclic ring system or a heterocyclic
ring contains 1 to 4 heteroatoms, which are independently
selected from N, 0, and S. A substitutable nitrogen on
an aromatic or non-aromatic heterocyclic ring may be
optionally substituted. N or S may also exist in
oxidized form such as N0, SO and 502.
One having ordinary skill in the art will
recognize that the maximum number of heteroatoms in a
stable, chemically feasible heterocyclic ring, whether it
is aromatic or non-aromatic, is determined by the size of
the ring, degree of unsaturation, and valence of the
heteroatoms. In general, a heterocyclic ring may have
one to four heteroatoms so long as the heterocyclic ring
is chemically feasible and stable.
The term "chemically stable arrangement" or
"chemically feasible and stable" as used herein, refers
to a compound structure that renders the ocmpound
sufficiently stable to allow manufacture and
administration to a mammal by methods known in the art.
Typically, such compounds are stable at a temperature of
40°C or less, in the absence of moisture or other
chemically reactive conditions, for at least a week.
According to a preferred embodiment, Q1
is selected from phenyl or pyridyl containing 1 to 3
substituents, wherein at least one of said substituents
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-15-
is in the ortho position and said substituents are
independently selected from chloro, fluoro, bromo, -CH3,
-OCH3, -OH, -CF3, -OCF3, -0 (CH2) 2CH3, NHS, 3, 4-
methylenedioxy, -N (CH3) ~, -NH-S (0) 2-phenyl, -NH-C (0) 0-CH2-
4-pyridine, -NH-C (0) CH2-morpholine, -NH-C (0) CHZ-N (CH3) ar
-NH-C (0) CH2-piperazine, -NH-C (0) CHI-pyrrolidine,
-NH-C(0)C(O)-morpholine, -NH-C(O)C(0)-piperazine,
-NH-C (0) C (0) -pyrrolidine, -0-C (0) CH2-N (CH3) ~, or
-0- ( CHI ) 2-N ( CH3 ) ~ .
Even more preferred are phenyl or pyridyl
containing at least 2 of the above-indicated substituents
both being in the ortho position.
Some specific examples of preferred Q1 are:
OC H3
OC H3
F H3C H3 ~ OCH3 F3C ~ F
r
CF3 HsCO / OCH3 H3 ~ Br
, , ,
H3 ~ CH3 C ~ CH3 C ~ C
r r r
w I w H2N I w
C ~ OCH3 H3 ~ OCH3 H3C ~ OCH3
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-16-
NH2
NH2 \ CI
H I ~ OCH H I ~ OCH
3 ~ 3 3 ~ 3 SCI
OC H3
\ ~ \ ' ~ ~ \
H3 ~ OCH3 ~ CI ~ H3 ~ OCH3
~
NH2 O H
NH2 I ~ OH
C ~ CI ~ CI ~ CI ~ CI
NH2
H3 ~ C H3
OC H3
OH I ~ I ~ OCH3
Hs ~ CHa H3 ~ CH3 C ~ OCH3
, ,
0 0
s
0 0 -~
0 0
ci ~ ci / c~ '~ ci
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-17-
H3C ~ CH3
OCH3 N
\ ~ \ OCH3 ~ \ ~ N\ OCH3
CI / G / CI / G ~ CI
r r r
N
OCH3 N
\ OCH3 ~ \ N
CI / CI / CI CI ~ ~ CI
r r r
O n
N ~~ N
N~ \ N
C CI ~ CI
r
O
N~N
CI
or ,
Most preferably, Q1 is selected from 2-fluoro-
6-trifluoromethylphenyl, 2,6-difluorophenyl, 2,6-
dichlorophenyl, 2-chloro-4-hydroxyphenyl, 2-chloro-4-
aminophenyl, 2,6-dichloro-4-aminophenyl, 2,6-dichloro-3-
aminophenyl, 2,6-dimethyl-4-hydroxyphenyl, 2-methoxy-3,5-
dichloro-4-pyridyl, 2-chloro-4,5 methylenedioxy phenyl,
or 2-chloro-4-(N-2-morpholino-acetamido)phenyl.
According to a preferred embodiment, Q2 is
phenyl, pyridyl or naphthyl containing 0 to 3
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-18-
substituents, wherein each substituent is independently
selected from chloro, fluoro, bromo, methyl, ethyl,
isopropyl, -OCH3, -OH, -NH2, -CF3, -OCF3, -SCH3, -OCH3,
-C (O) OH, -C (0) OCH3, -CHZNH~, -N (CH3) 2, -CHZ-pyrrolidine and
-CH20H .
Some specific examples of preferred Q2 are:
/ ~ / ~ / ~ \
/ CF3
OH C02H OGH3
,
\ ~ SCH3 \ CF3
SCH3 I / I / / CI
CI ~ CH3 I ~ CH3 \ CI
/ / CH3 / C1
, ,
F C H3
F \ F ~ C H3
F I / I / I /
/ ~H2 NH2 OC H3
,
CI F
\ CI F \ F
~/ ~/ \
OCH3 CH3 OCH~ GH3
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-19-
\
F
\ CHs CH \
/ /
CI CHs F
\ \
/ (/ /
CHs 02CH3 Br
r ,
F I ~ CI I \ CI \ F
/ / /
COZH 02H O2CH3 O2CH3
r r r r
CI I \ I ~ I ~ CI
I/ i ~ i
H2 NH2 N(C H3)2 NH2
r r r
F ~ CI
CI I / I / \ F
/
N(CH3)2
NH2
F ~ CI \ F
/
N(CH3)2 OH OH
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-20-
F
H~NH
H H'2~N
. . ,
F I \ CI
F
~NH \NH
H2N \NH H2~NH ~02H
~ . .
\ I \ F I \ CI
CI
NH NH NH
H~N H~N H~N
F ~ ~ F ~ ~ F ~ ~ F
i s i
CH3 CI F OH
. . .
F
F ~ ~ ~ \ ~ /
~CI / / I
OH ~ OH ~ ,
unsubstituted 2-pyridyl or unsubstituted phenyl.
Most preferred are compounds wherein Q2 is
selected from phenyl, 2-isopropylphenyl, 3,4-
dimethylphenyl, 2-ethylphenyl, 3-fluorophenyl, 2-
methylphenyl, 3-chloro-4-fluorophenyl, 3-chlorophenyl, 2-
carbomethoxylphenyl, 2-carboxyphenyl, 2-methyl-4-
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-21-
chlorophenyl, 2-bromophenyl, 2-pyridyl, 2-
methylenehydroxyphenyl, 4-fluorophenyl, 2-methyl-4-
fluorophenyl, 2-chloro-4-fluorphenyl, 2,4-difluorophenyl,
2-hydroxy-4-fluorphenyl, 2-methylenehydroxy-4-
fluorophenyl, 1-naphthyl, 3-chloro-2-methylenehydroxy, 3-
chloro-2-methyl, or 4-fluoro-2-methyl.
According to another preferred embodiment, R~
is a halogen. In a more preferred embodiment, R~ is Cl.
According to another preferred embodiment, each
Y is C.
According an even more preferred embodiment,
each Y is C and the R and U attached to each Y component
is hydrogen.
Some specific examples of preferred J are:
0 O
O ~
~O~ N
/~O~ N I O NI
i N ~N
N
~ , , ~NH, and
O
~O~ N
N
~N~
According to another preferred embodiment, K is
a 0-4 atom chain terminating in an ester.
According to another preferred embodiment, M is
0.
Some specific examples of preferred K are:
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-22-
O O O
/~O~ NH2 ~O NH2 ~O NH2
O O O
NH2 ~O NH2 ~O NH2
OH
O OH O OH
O
O O O
/~,O ~O NH2 ~p NH2
OH
OH OH
O
O O O
~O~NH2 ~O NH2 ~O NH2
O O O
O NH2 ~O NH2 ~O NH2
OH
O~ OH O OH
O
O O
O ~O NH2 ~O NH2
OH
OH OH
O
O
~~OH ~~OH
~O~P~OH ~O,P.OH
i
N
O O O
~O ~ ~ ~O ~ ~O NH2
N
~N
More preferably, K is selected from:
O O
NH2 ~O NH2
~.OH ~.OH
~O.P.OH ~ or ~p~P~OH ,
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-23-
Some preferred embodiments are provided in
Tables 1 to 3 below:
Table 1.
Cmpd Structure Cmpd Structure
Nmbr Nmbr
101 I w 10~ I \
i
F ~ ~F I F I F ~O
O~N ~ \ I~N\ O~N I \ I~N
NH2 N / O~N NH2 N ~ O~N
F , IO' F , IIO
F F
103 I w 104 I ~
i
F F F I F
O~N I ~ HZN~NHZ O~N ~ ~ I~NH2
NHF N ~ O O N NH2 N / OuN
F , 'I0
F F
105 ~ 106
O
F I F I F F
O\'N I ~ ~N~ O\'N I ~ \'N.J
NHS N ~ O~N NH2 N / OuN
F / IOI F , I IO
W W
F F
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-2.4-
Table 1 (cont.
Cmpd Structure Cmpd Structure
Nmbr Nmbr
107 ~ 108 ~
F I / F F I ~ F O
O N ~ N~ O
I~ ~ ~ I~
~N N ~ OuN ~N N i O~N
~N~ F , IOI N F / IIO
I coy , I
F F
109 ~ 110
F I ~ F N F ( i F N
O N O N
I~ ~ ~ ~ I~
N H2 N ~ O~ N ~ N N / O~ N
F \ I O CN\ F \ I O
JlN
F F
CA 02418389 2003-02-04
.",.
wo o2na2s1 '~ il~:;~e.l..", ~ .f~rcTiuson2sois"°;i~ !1.":l, .:al,.
~',~:i;
-25-
Table 2.
Cmpd Structure Cmpd Structure
Nmbr Nmbr
111 ~ O 112 ~ O
z II
F I F H N ~O F I ~ F H2N ~O
O~ N I ~ ~ O~ N
NHz N i O~ NH NHz N i O~ NH
'0I / I IO
F F
113 I ~ O 114 I ~ O
H2N' ~ ~ HO
F F ~O F I F ~~O
~~ N I \ ~ o~ N I ~ o
NHz N i O~NH NHz N i O~NH
'0I ~ I IO
I
F F
115 ~ O 116 I ~. O
F I ~ F HO~ PLO F ~ F HzN v 'O
O\'N I ~ ~ O\/N I ~ HO'
NHz N i O~ NH NHz N i O~ NH
'0I / I'O
I
F F
117 w O
~ H~
F F ~ O
O~ N I W
NHz N i O~ NH
O
I
F
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-2 6-
Table 3.
Cmpd Structure Cmpd Structure
Nmbr Nmbr
118 ~ 119
F I / F F I i F
O HN N ~ ~~, NH O~ N I
z z NHz N ~ NHz
O' '-O
I I ~O O
CI \ CI
120 ~ 121
F I / F F I / F
OH
O NHN N / I~, NH O~ N I
z 2 NHz N / ~.,,. NHz
O~O
I \ I ~O O
CI CI
122 ~ 123
F I ~ F F I ~ F
O~N I w OH O~N I W
NHz N ~ O NHz N ~ OH
I ,OH
I O O \ I O'
'CI ~CI
124 ~ 125
F I ~ F F I ~ F
O N O N
z N i ~~NH ~ z N / HOzC~~, NHz
I 'O O \ I ~O O
CI CI
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
Particularly preferred embodiments include:
O
"N H2
O ~ ~Ar
XO~
N
H
F
wherein Ar is F or F
O O
NH~~ HO-P.~
and X = ~ or HO
Particularly preferred embodiments also
include:
O
_ 'NHZ
F
F ~ F
wherein Ar is or
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-28-
Other particularly preferred embodiments
include:
'N~
'r
F
F ~ F
wherein Ar is or
Other particularly preferred embodiments
O O
NH2~ HO-P~
wherein X = ~ or HO .
include:
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-29-
Other particularly preferred embodiments
include:
NH2
X
H 2N~
0
O O
NH2~ HO-P.~
wherein X = ~ or HO/ .
Other particularly preferred embodiments
include:
FO
N"NH2
X~NfiO ~F
N~ ~ M a
wherein X is N (CH3) ~, ~ or ~ .
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-30-
include:
Y
_N
H
Other particularly preferred embodiments
O
"N H2
wherein Y = Me or H; and X = ( CH2 ) 3, CHIC ( CH3 ) ~CH2,
CHIN (Me ) C ( 0 ) CH2 .
Some most preferred embodiments include:
H
H 2N ~ HO ~ O~ F
O ~ O
F
NH2
F
F I~- U- ~ ' F
~N
and
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-31-
According to another embodiment, the present
invention provides methods of producing the above-
identified compounds of the formulae (Ia),(Ib), (Ic) or
(Id). Representative synthesis schemes are depicted
below. In all schemes, the h1 and L2 groups on the
initial materials are meant to represent leaving groups
ortho to the nitrogen atom in a heterocyclic ring. For
example, compound A may be 2,6-dichloro-3 vitro pyridine.
crhor,o i
R R
Y Y y ~ --~ 1) Q~-NHZ Q1 ~-~ O
L~~ ~ CHO > L~~ ~ ' HN
N N 2) hydrolyze N--~~H
L2 L2 ~~ L2
1
R
Q1 Y Y Q1 RY Y O Q1 RY Y O
V N~ ~ H ~ HN~ ~ H
Q2 Q2 Q2
One having skill in the art will recognize
Scheme 1 may be used to synthesize compounds having the
general formula of (Ia), (Ib), (Ic) and (Id).
According to another embodiment of the
invention, the activity of the p38 inhibitors of this
invention may be assayed in vitro, in vi Yo or in a cell
line. In vitro assays include assays that determine
inhibition of either the kinase activity or ATPase
activity of activated p38. Alternate in vitro assays
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-32-
quantitate the ability of the inhibitor to bind to p38
and may be measured either by radiolabelling the
inhibitor prior to binding, isolating the inhibitorJp38
complex and determining the amount of radiolabel bound,
or by running a competition experiment where new
inhibitors are incubated with p38 bound to known
radioligands.
Cell culture assays of the inhibitory effect of
the compounds of this invention may determine the amounts
of TNF, IL-1, IL-6 or IL-8 produced in whole blood or
cell fractions thereof in cells treated with inhibitor as
compared to cells treated with negative controls. Level
of these cytokines may be determined through the use of
commercially available ELISAs.
An in vivo assay useful for determining the
inhibitory activity of the p38 inhibitors of this
invention are the suppression of hind paw edema in rats
with Mycobacterium butyricum-induced adjuvant arthritis.
This is described in J.C. Boehm et al., J. Med. Chem.,
39, pp. 3929-37 (1996), the disclosure of which is herein
incorporated by reference. The p38 inhibitors of this
invention may also be assayed in animal models of
arthritis, bone resorption, endotoxin shock and immune
function, as described in A. M. Badger et al., J.
Pharmacol. Experimental Therapeutics, 279, pp. 1453-61
(1996), the disclosure of which is herein incorporated by
reference.
The p38 inhibitors or pharmaceutical salts
thereof may be formulated into pharmaceutical
compositions for administration to animals or humans.
These pharmaceutical compositions, which comprise an
amount of p38 inhibitor effective to treat or prevent a
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-33-
p38-mediated condition and a pharmaceutically acceptable
carrier, are another embodiment of the present invention.
The term "p38-mediated condition", as used
herein means any disease or other deleterious condition
in which p38 is known to play a role. This includes
conditions known to be caused by IL-1, TNF, IL-6 or IL-8
overproduction. Such conditions include, without
limitation, inflammatory diseases, autoimmune diseases,
destructive bone disorders, proliferative disorders,
infectious diseases, neurodegenerative diseases,
allergies, reperfusionlischemia in stroke, heart attacks,
angiogenic disorders, organ hypoxia, vascular
hyperplasia, cardiac hypertrophy, thrombin-induced
platelet aggregation, and conditions associated with
prostaglandin endoperoxidase synthase-2.
Inflammatory diseases which may be treated or
prevented by the compounds of this invention include, but
are not limited to, acute pancreatitis, chronic
pancreatitis, asthma, allergies, and adult respiratory
distress syndrome.
Autoimmune diseases which may be treated or
prevented by the compounds of this invention include, but
are not limited to, glomerulonephritis, rheumatoid
arthritis, systemic lupus erythematosus, scleroderma,
chronic thyroiditis, Graves' disease, autoimmune
gastritis, diabetes, autoimmune hemolytic anemia,
autoimmune neutropenia, thrombocytopenia, atopic
dermatitis, chronic active hepatitis, myasthenia gravis,
multiple sclerosis, inflammatory bowel disease,
ulcerative colitis, Crohn's disease, psoriasis, or graft
vs. host disease.
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-34-
Destructive bone disorders which may be treated
or prevented by the compounds of this invention include,
but are not limited to, osteoporosis, osteoarthritis and
multiple myeloma-related bone disorder.
Proliferative diseases which may be treated or
prevented by the compounds of this invention include, but
are not limited to, acute myelogenous leukemia, chronic
myelogenous leukemia, metastatic melanoma, Kaposi's
sarcoma, and multiple myeloma.
Angiogenic disorders which may be treated or
prevented by the compounds of this invention include
solid tumors, ocular neovasculization, infantile
haemangiomas.
Infectious diseases which may be treated or
prevented by the compounds of this invention include, but
are not limited to, sepsis, septic shock, and
Shigellosis.
Viral diseases which may be treated or
prevented by the compounds of this invention include, but
are not limited to, acute hepatitis infection (including
hepatitis A, hepatitis B and hepatitis C), HIV infection
and CMV retinitis.
Neurodegenerative diseases which may be treated
or prevented by the compounds of this invention include,
but are not limited to, Alzheimer's disease, Parkinson's
disease, cerebral ischemias or neurodegenerative disease
caused by traumatic injury.
"p38-mediated conditions" also include
ischemia/reperfusion in stroke, heart attacks, myocardial
ischemia, organ hypoxia, vascular hyperplasia, cardiac
hypertrophy, and thrombin-induced platelet aggregation.
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-35-
In addition, p38 inhibitors of the instant
invention are also capable of inhibiting the expression
of inducible pro-inflammatory proteins such as
prostaglandin endoperoxide synthase-2 (PGHS-2), also
referred to as cyclooxygenase-2 (COX-2). Therefore, other
"p38-mediated conditions" which may be treated by the
compounds of this invention include edema, analgesia,
fever and pain, such as neuromuscular pain, headache,
cancer pain, dental pain and arthritis pain.
The diseases that may be treated or prevented
by the p38 inhibitors of this invention may also be
conveniently grouped by the cytokine (IL-l, TNF, IL-6,
IL-8) that is believed to be responsible for the disease.
Thus, an IL-1-mediated disease or condition
includes rheumatoid arthritis, osteoarthritis, stroke,
endotoxemia and/or toxic shock syndrome, inflammatory
reaction induced by endotoxin, inflammatory bowel
disease, tuberculosis, atherosclerosis, muscle
degeneration, cachexia, psoriatic arthritis, Reiter's
syndrome, gout, traumatic arthritis, rubella arthritis,
acute synovitis, diabetes, pancreatic f3-cell disease and
Alzheimer's disease.
TNF-mediated disease or condition includes,
rheumatoid arthritis, rheumatoid spondylitis,
osteoarthritis, gouty arthritis and other arthritic
conditions, sepsis, septic shock, endotoxic shock, gram
negative sepsis, toxic shock syndrome, adult respiratory
distress syndrome, cerebral malaria, chronic pulmonary
inflammatory disease, silicosis, pulmonary sarcoidosis,
bone resorption diseases, reperfusion injury, graft vs.
host reaction, allograft rejections, fever and myalgias
due to infection, cachexia secondary to infection, AIDS,
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-3 6-
ARC or malignancy, keloid formation, scar tissue
formation, Crohn's disease, ulcerative colitis or
pyresis. TNF-mediated diseases also include viral
infections, such as HIV, CMV, influenza and herpes; and
veterinary viral infections, such as lentivirus
infections, including, but not limited to equine
infectious anemia virus, caprine arthritis virus, visna
virus or maedi virus; or retrovirus infections, including
feline immunodeficiency virus, bovine immunodeficiency
virus, or canine immunodeficiency virus.
IL-8 mediated disease or condition includes
diseases characterized by massive neutrophil
infiltration, such as psoriasis, inflammatory bowel
disease, asthma, cardiac and renal reperfusion injury,
adult respiratory distress syndrome, thrombosis and
glomerulonephritis.
In addition, the compounds of this invention
may be used topically to treat or prevent conditions
caused or exacerbated by IL-1 or TNF. Such conditions
include inflamed joints, eczema, psoriasis, inflammatory
skin conditions such as sunburn, inflammatory eye
conditions such as conjunctivitis, pyresis, pain and
other conditions associated with inflammation.
According to another embodiment, the compounds
of this invention may be used to treat ZAP70-mediated
conditions including, without limitation, organ or tissue
rejection associated with transplantation, autoimune
disease, e.g., rheumatoid arthritis, systemic lupus
erythematosus (SLE), psoriasis, Sjogren's Syndrome,
thyroiditis, pulmonary fibrosis, bronchiolitis
obliterans, hemolytic anemia and Wegener's
granulomatosis, cancer, including leukemia and lymphoma,
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-37-
multiple sclerosis, graft versus host disease, and
Kawasaki syndrome.
The ZAP70 inhibitors or pharmaceutical salts
thereof may be formulated into pharmaceutical
compositions for administration to animals or humans.
These pharmaceutical compositions, which comprise an
amount of ZAP70 inhibitor effective to treat or prevent a
ZAP70-mediated condition and a pharmaceutically
acceptable carrier, are another embodiment of the present
invention.
In addition to the compounds of this invention,
pharmaceutically acceptable salts of the compounds of
this invention may also be employed in compositions to
treat or prevent the above-identified disorders.
Pharmaceutically acceptable salts of the
compounds of this invention include those derived from
pharmaceutically acceptable inorganic and organic acids
and bases. Examples of suitable acid salts include
acetate, adipate, alginate, aspartate, benzoate,
benzenesulfonate, bisulfate, butyrate, citrate,
camphorate, camphorsulfonate, cyclopentanepropionate,
digluconate, dodecylsulfate, ethanesulfonate, formate,
fumarate, glucoheptanoate, glycerophosphate, glycolate,
hemisulfate, heptanoate, hexanoate, hydrochloride,
hydrobromide, hydroiodide, 2-hydroxyethanesulfonate,
lactate, maleate, malonate, methanesulfonate, 2-
naphthalenesulfonate, nicotinate, nitrate, oxalate,
palmoate, pectinate, persulfate, 3-phenylpropionate,
phosphate, picrate, pivalate, propionate, salicylate,
succinate, sulfate, tartrate, thiocyanate, tosylate and
undecanoate. Other acids, such as oxalic, while not in
themselves pharmaceutically acceptable, may be employed
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-38-
in the preparation of salts useful as intermediates in
obtaining the compounds of the invention and their
pharmaceutically acceptable acid addition salts.
Salts derived from appropriate bases include alkali metal
(e. g., sodium and potassium), alkaline earth metal (e. g.,
magnesium), ammonium and N-(C1-4 alkyl)4+ salts. This
invention also envisions the quaternization of any basic
nitrogen-containing groups of the compounds disclosed
herein. Water or oil-soluble or dispersible products may
be obtained by such quaternization.
Pharmaceutically acceptable carriers that may
be used in these pharmaceutical compositions include, but
are not limited to, ion exchangers, alumina, aluminum
stearate, lecithin, serum proteins, such as human serum
albumin, buffer substances such as phosphates, glycine,
sorbic acid, potassium sorbate, partial glyceride
mixtures of saturated vegetable fatty acids, water, salts
or electrolytes, such as protamine sulfate, disodium
hydrogen phosphate, potassium hydrogen phosphate, sodium
chloride, zinc salts, colloidal silica, magnesium
trisilicate, polyvinyl pyrrolidone, cellulose-based
substances, polyethylene glycol, sodium
carboxymethylcellulose, polyacrylates, waxes,
polyethylene-polyoxypropylene-block polymers,
polyethylene glycol and wool fat.
The compositions of the present invention may
be administered orally, parenterally, by inhalation
spray, topically, rectally, nasally, buccally, vaginally
or via an implanted reservoir. The term "parenteral" as
used herein includes subcutaneous, intravenous,
intramuscular, intra-articular, intra-synovial,
intrasternal, intrathecal, intrahepatic, intralesional
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-39-
and intracranial injection or infusion techniques.
Preferably, the compositions are administered orally,
intraperitoneally or intravenously.
Sterile injectable forms of the compositions of
this invention may be aqueous or oleaginous suspension.
These suspensions may be formulated according to
techniques known in the art using suitable dispersing or
wetting agents and suspending agents. The sterile
injectable preparation may also be a sterile injectable
solution or suspension in a non-toxic parenterally-
acceptable diluent or solvent, for example as a solution
in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's
solution and isotonic sodium chloride solution. In
addition, sterile, fixed oils are conventionally employed
as a solvent or suspending medium. For this purpose, any
bland fixed oil may be employed including synthetic mono-
or di-glycerides. Fatty acids, such as oleic acid and
its glyceride derivatives are useful in the preparation
of injectables, as are natural pharmaceutically-
acceptable oils, such as olive oil or castor oil,
especially in their polyoxyethylated versions. These oil
solutions or suspensions may also contain a long-chain
alcohol diluent or dispersant, such as carboxymethyl
cellulose or similar dispersing agents which are commonly
used in the formulation of pharmaceutically acceptable
dosage forms including emulsions and suspensions. Other
commonly used surfactants, such as Tweens, Spans and
other emulsifying agents or bioavailability enhancers
which are commonly used in the manufacture of
pharmaceutically acceptable solid, liquid, or other
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-40-
dosage forms may also be used for the purposes of
formulation.
The pharmaceutical compositions of this
invention may be orally administered in any orally
acceptable dosage form including, but not limited to,
capsules, tablets, aqueous suspensions or solutions. In
the case of tablets for oral use, carriers commonly used
include lactose and corn starch. Lubricating agents,
such as magnesium stearate, are also typically added.
For oral administration in a capsule form, useful
diluents include lactose and dried cornstarch. When
aqueous suspensions are required for oral use, the active
ingredient is combined with emulsifying and suspending
agents. If desired, certain sweetening, flavoring or
coloring agents may also be added.
Alternatively, the pharmaceutical compositions
of this invention may be administered in the form of
suppositories for rectal administration. These can be
prepared by mixing the agent with a suitable non-
irritating excipient which is solid at room temperature
but liquid at rectal temperature and therefore will melt
in the rectum to release the drug. Such materials
include cocoa butter, beeswax and polyethylene glycols.
The pharmaceutical compositions of this
invention may also be administered topically, especially
when the target of treatment includes areas or organs
readily accessible by topical application, including
diseases of the eye, the skin, or the lower intestinal
tract. Suitable topical formulations are readily
prepared for each of these areas or organs.
Topical application for the lower intestinal
tract can be effected in a rectal suppository formulation
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-41-
(see above) or in a suitable enema formulation.
Topically-transdermal patches may also be used.
E'or topical applications, the pharmaceutical
compositions may be formulated in a suitable ointment
containing the active component suspended or dissolved in
one or more carriers. Carriers for topical
administration of the compounds of this invention
include, but are not limited to, mineral oil, liquid
petrolatum, white petrolatum, propylene glycol,
polyoxyethylene, polyoxypropylene compound, emulsifying
wax and water. Alternatively, the pharmaceutical
compositions can be formulated in a suitable lotion or
cream containing the active components suspended or
dissolved in one or more pharmaceutically acceptable
carriers. Suitable carriers include, but are not limited
to, mineral oil, sorbitan monostearate, polysorbate 60,
cetyl esters wax, cetearyl alcohol, 2-octyldodecanol,
benzyl alcohol and water.
For ophthalmic use, the pharmaceutical
compositions may be formulated as micronized suspensions
in isotonic, pH adjusted sterile saline, or, preferably,
as solutions in isotonic, pH adjusted sterile saline,
either with or without a preservative such as
benzylalkonium chloride. Alternatively, for ophthalmic
uses, the pharmaceutical compositions may be formulated
in an ointment such as petrolatum.
The pharmaceutical compositions of this
invention may also be administered by nasal aerosol or
inhalation. Such compositions are prepared according to
techniques well-known in the art of pharmaceutical
formulation and may be prepared as solutions in saline,
employing benzyl alcohol or other suitable preservatives,
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-42-
absorption promoters to enhance bioavailability,
fluorocarbons, and/or other conventional solubilizing or
dispersing agents.
The amount of p38 or ZAP70 inhibitor that may
be combined with the carrier materials to produce a
single dosage form will vary depending upon the host
treated and the particular mode of administration.
Preferably, the compositions should be formulated so that
a dosage of between 0.01 - 100 mgjkg body weight/day of
the inhibitor can be administered to a patient receiving
these compositions.
It should also be understood that a specific
dosage and treatment regimen for any particular patient
will depend upon a variety of factors, including the
activity of the specific compound employed, the age, body
weight, general health, sex, diet, time of
administration, rate of excretion, drug combination, and
the judgment of the treating physician and the severity
of the particular disease being treated. The amount of
inhibitor will also depend upon the particular compound
in the composition.
According to another embodiment, the invention
provides methods for treating or preventing a p38-
mediated condition comprising the step of administering
to a patient one of the above-described pharmaceutical
compositions. The term "patient", as used herein, means
an animal, preferably a human.
Preferably, that method is used to treat or
prevent a condition selected from inflammatory diseases,
autoimmune diseases, destructive bone disorders,
proliferative disorders, infectious diseases,
degenerative diseases, allergies, reperfusion/ischemia in
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-43-
stroke, heart attacks, angiogenic disorders, organ
hypoxia, vascular hyperplasia, cardiac hypertrophy, and
thrombin-induced platelet aggregation.
According to another embodiment, the inhibitors
of this invention are used to treat or prevent an IL-1,
IL-6, IL-8 or TNF-mediated disease or condition. Such
conditions are described above.
Depending upon the particular p38-mediated
condition to be treated or prevented, additional drugs,
which are normally administered to treat or prevent that
condition, may be administered together with the
inhibitors of this invention. For example,
chemotherapeutic agents or other anti-proliferative
agents may be combined with the p38 inhibitors of this
invention to treat proliferative diseases.
Those additional agents may be administered
separately, as part of a multiple dosage regimen, from
the p38 inhibitor-containing composition. Alternatively,
those agents may be part of a single dosage form, mixed
together with the p38 inhibitor in a single composition.
According to another embodiment, the invention
provides methods for treating or preventing a ZAP70-
mediated condition comprising the step of administering
to a patient one of the above-described pharmaceutical
compositions.
In order that the invention described herein
may be more fully understood, the following examples are
set forth. It should be understood that these examples
are for illustrative purposes only and are not to be
construed as limiting this invention in any manner.
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-44
'CVTT?DT'G~ 'I
Synthesis of p38 Inhibitor Compound 7
Br Br
~N ~ ~N
~ Br ~ ~ Br
CHO
1
To a solution of LDA (60mmo1, 40mLs) at -78° C,
was added dropwise a solution of 2,6-dibromopyridine
(40mmo1, 9.48gms) in THF (30mLs, dried). The mixture was
stirred at -78° C for 20 minutes. Ethyl formate (400mmo1,
32.3mLs) was added and stirring was continued at -78° C
for 2 hours. Saturated ammonium chloride (200mLs) was
added and the mixture was warmed to room temperature.
The reaction mixture was diluted with ethyl acetate and
the organic layer was washed with aqueous acid and base.
The organic layer was dried and evaporated in vacuo. The
resulting material was purified by flash chromatography
on silica gel followed by eluting with loo ethyl acetate
in n-hexane to afford 1 (32mmo1, 8.41gms) as a white
solid.
Br gr
~N
Br I ~ Br
O H O O
J
1 2
A solution of 1 (776 mmol, 205.6 gms) and
triethyl orthoformate (200 mL) dissolved in ethanol (750
mL) was refluxed overnight. The reaction mixture was
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-45-
cooled, and evaporated in vacuo. The remaining red oil
was dissolved in hexane and filtered over a plug of
silica gel. The plug was eluted with 50o CH2C1~/hexane.
The filtrate was evaporated to afford 2 as an oil.
F
r ~ I NH
~N F
I ~N
~Br /
~Br
O H
2
To a suspension of 60o NaH (130 mmol, 5.20 g)
and 2 (61.2 mmol, 20.76 g) in THF (100 mL) at reflux was
added dropwise a solution of 2,6-difluoroaniline (61.3
mmol, 20 g) in THF (100 mL). After the aniline had been
added, Pd (PPh3) 4 (100 mg) was added. The mixture was
refluxed for one hour and cooled. Hydrochloric acid (1N,
100 mL) was added and stirring was continued for one
hour. The reaction mixture was extracted with CHZC12.
The organic extract was dried and evaporated in Vacuo.
The resulting material was dissolved in a minimal amount
of CH2C12 and hexane was added. The solution was cooled
precipitating 3 as a yellow solid.
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-46-
F F
\I \
~NH -NH
F I ~ F I ~N
/ Br / ~ \
O H O H ~F
3 4
p-fluorophenylboronic acid (57.5 mmol, 8.05 g),
and 3 (96.9 mmol, 14.70 g) were dissolved in a
dimethoxyethane (300 mL). Cesium fluoride (68.6 mmol,
10.42 g) and tetrakis(triphenylphosphine)palladium (0)
(100 mgs) were added to the solution and the suspension
was allowed to reflux overnight. The reaction mixture
was poured into water and extracted with CH2C12. The
organic extract was washed with 1N NaOH, dried with MgS09,
and filtered over a plug of silica gel. The plug was
eluted with CH~C1~ and the filtrate was evaporated in
vacuo. The resulting yellow solid was triturated with
50 o CH2C1~/hexane to afford 4 ( 9 . 50g, 62 0 ) as a yellow
solid.
/ F
'NH
F ~N
\
O H
F F
4 5
A solution of 4 (70.1 mmol~ 23.01 g) in toluene
(250 mL) was combined with a 20o solution of phosgene in
toluene (151 mmol, 80 mL) and heated to reflux for two
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-47-
hours. The reaction was cooled and poured into ammonium
hydroxide. The mixture was stirred for five minutes and
extracted with methylene chloride. The organic extract
was dried and filtered over a plug of silica gel. The
plug was eluted with methylene chloride to remove
residual starting material. It was then eluted with 50o
ethyl acetate/methylene chloride to obtain 5. The
filtrate was evaporated in Yacuo to afford 5 (21.38 g,
860) as a white solid.
F
5 6
Sodium borohydride (36.5 mmol, 1.38 g) was
added to a solution of 5 (60.0 mmol, 21.38 g) in THF (100
mL) and the solution was stirred for one hour at 0°C and
then two hours at room temperature. The reaction was
poured into 1N HCl and extracted with methylene chloride.
The organic extract was dried and filtered over a plug of
silica gel. The plug was eluted with 5% ethyl
acetate/methylene chloride to remove residual starting
material. It was then eluted with ethyl acetate to
obtain 6. The filtrate was evaporated to afford 6 as a
white solid.
The spectral data for compound 6 was:
1H NMR (500 MHz, CDC13) 8 7 . 90 (d, 1H) , 7 . 60 (d, 2H) , 7 . 5-
7.3 (m, 5H), 6.30 (d, 2H), 4.5 (s, 2H), 2.3 (s, 2H).
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
_48-
H
6 7
A solution of 6 (2.79 mmol, 1.00 g) and p-
nitrophenyl chloroformate (5.56 mmol, 1.12 g) was cooled
to 0°C. Triethylamine (14.3 mmol, 2.0 mL) was added and
the solution was stirred for 15 minutes and poured into
ammonium hydroxide. The solution mixture was poured into
water and extracted with methylene chloride. The organic
extract was washed with saturated aqueous sodium
bicarbonate, dried, and evaporated in vacuo to afford 7
(730 mg, 650) as a white solid.
w7w.rnT n
Synthesis of p38 Inhibitor Prodrugs 9 and 10
H F JI
9
A mixture of 8 (1.0 g, 2.30 mmol) and N,N-
dimethylformamide dimethyl acetal (1.01 g, 6.91 mmol) in
10 mL of toluene was heated to 80°C for 20 minutes. The
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-49-
resulting solution was cooled to room temperature.
Normal workup followed by chromatography on silica gel
(hexane/EtOAc: 1014) gave amidine 9 (compound 101 of
Table 1) as a white solid. The spectral data for
compound 9 was: 1H NMR (500 MHz, CDC13) 88.3 (s, 1H), 7.7
(d, 1H), 7.5-7.4 (m, 1H), 7.1-7.0 (m, 1H), 6.95-6.85 (t,
2H), 6.85-6.75 (m, 1H), 6.45-6.4 (d, 1H), 6.2 (s, 1H),
4.95 (s, 2H), 3.05 (s, 3H), 2.95 (s, 3H).
F O
N~N
F
H
$ 10
A mixture of 8 ( 1 . 0 g, 2 . 30 mmol ) and N, N-
dimethylformamide dimethyl acetal (3.3 g, 22.4 mmol) in
10 mL of toluene was heated to 80°C for 90 minutes. The
resulting solution was cooled to room temperature.
Normal workup followed by chromatography on silica gel
(hexane/EtOAc: 2/1) gave bis-amidine 10 (compound 107 of
Table 1) as a white solid. The spectral data for
compound 10 was: 1H NMR (500 MHz, CDC13) 8 8.4 (s, 1H) ,
8.3 (s, 1H), 8.05-7.95 (s, 1H), 7.15-7.05 (m, 2H), 6.85-
6.75 (t, 2H) , 6.75-6. 65 (m, 4H) , 4 . 95 (s, 2H) , 3 . 0-2. 95
(d, 9H), 2.65 (s, 3H).
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-50-
1'~VTTA'7~T L~ 7
Synthesis of p38 Inhibitor Prodrug 13
"NH2
F
~N F ,
/ \
HO v 'F
6 11
To a mixture of 6 (1.25gm, 3.35mmo1) and 4-
nitrophenyl chloroformate (0.81gm, 4.02mmo1) in
tetrahydrofuran (30mL) was added triethylamine (1.16mL,
8.38mmo1) dropwise at 0°C . The resulting slurry was
allowed to stir at 0°C for 30 minutes. Ethanolamine
(0.6mL, lO.Ommo1) was added and the solution was stirred
at 0°C for 30 minutes. Normal work-up followed by
chromatography on silica (hexane/acetone: 10/4) gave 11
(1.03gm, 2.23mmo1) as a white solid. 1H NMR (500 MHz,
CDC13) 7.75 (d, 1H), 7.65-7.55 (m, 2H), 7.5-7.4 (m, 1H),
7.25-7.15 (t, 2H), 7.15-7.05 (t, 2H), 6.4 (d, 1H), 5.2-
5.1 (bs, 1H), 5.15 (s,2H), 3.75-3.65 (t, 2H), 3.4-3.3 (m,
2H) .
F
11 12
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-51-
A mixture of 11 (1.03gm, 2.23mmo1), (L)-BOC-
Val-OH (0.97gm, 4.46mmo1), and 1-(3-dimethylaminopropyl)
3-ethylcarbodiimide hydrochloride in. methylene chloride
(30mL) was stirred at room temperature for 1.5 hours.
Normal work-up followed by chromatography on silica
(hexanelacetone: 10/4) gave Val deriv. 12 (1.38gms,
2.09mmo1) as a white solid. 1H NMR (500 MHz, CDC13) 7.75
(d, 1H), 7.65-7.55 (m, 2H), 7.5-7.4 (m, 1H), 7.25-7.15
(t, 2H), 7.15-7.05 (t, 2H), 6.4 (d, 1H), 5.40-5.35 (bs,
1H), 5.05 (s, 2H), 5.00-4.95 (d, 1H), 4.4-4.3 (m, 1H),
4.25-4.15 (m, 1H), 4.15-4.05 (m, 1H), 3.55-3.45 (m, 2H),
2.15-2.05 (m, 1H)~ 1.45 (s, 9H), 1.0-0.85 (m, 6H).
~. .F
H
13
To a solution of 12 (1.38gms, 2.09mmo1) in
methylene chloride (20mLs) was added trifluoroacetic acid
(lOmLs). The solution was allowed to stir at room
temperature for 1 hour. Normal work-up gave a white solid
that was converted to its hydrochloride salt to give 13
(Compound 111 of Table 2; 0.61gms, 1.02mmo1) as a white
solid. The spectral data for compound 13 was: 1H NMR
(500 MHz, CDC13) 7.65 (d, 1H), 7.55-7.45 (m, 2H), 7.4-7.3
(m, 1H), 7.15-7.05 (m, 2H), 7.05-6.95 (m, 2H), 6.35 (d,
1H), 5.05-5.00 (bs, 1H), 4.95 (s, 2H), 4.15-4.05 (m, 2H),
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-52-
3.45-3.25 (m, 2H), 3.2 (s, 1H), 1.95-1.85 (m, 1H), 0.90-
0.75 (m, 6H).
L~VTTiTTT T /I
Cloning of p38 Kinase in Insect Cells
Two splice variants of human p38 kinase, CSBP1
and CSBP2, have been identified. Specific
oligonucleotide primers were used to amplify the coding
region of CSBP2 cDNA using a HeLa cell library
(Stratagene) as a template. The polymerase chain
reaction product was cloned into the pET-15b vector
(Novagen). The baculovirus transfer vector, pVL-(His)6-
p38 was constructed by subcloning a XbaI-BamHI fragment
of pETl5b-(His)6-p38 into the complementary sites in
plasmid pVL1392 (Pharmingen).
The plasmid pVL-(His)6-p38 directed the
synthesis of a recombinant protein consisting of a 23-
residue peptide (MGSSHHHHHHSSGLVPFtGSHMLE, where LVPRGS
represents a thrombin cleavage site) fused in frame to
the N-terminus of p38, as confirmed by DNA sequencing and
by N-terminal sequencing of the expressed protein.
Monolayer culture of Spodoptera frugiperda (Sf9) insect
cells (ATCC) was maintained in TNM-FH medium (Gibco BRL)
supplemented with 10o fetal bovine serum in a T-flask at
27°C. Sf9 cells in log phase were co-transfected with
linear viral DNA of Autographa califonica nuclear
polyhedrosis virus (Pharmingen) and transfer vector pVL-
(His)6-p38 using Lipofectin (Invitrogen). The individual
recombinant baculovirus clones were purified by plaque
assay using to low melting agarose.
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-53-
Fi'YZ1MDT.Ta' 5
Expression and Purification of Recombinant p38 Kinase
Trichoplusia ni (Tn-368) High-Five'n' cells
(Invitrogen) were grown in suspension in Excel-405
protein free medium (JRH Bioscience) in a shaker flask at
27°C. Cells at a density of 1.5 X 106 cells/ml were
infected with the recombinant baculovirus described above
at a multiplicity of. infection of 5. The expression
level of recombinant p38 was monitored by immunoblotting
using a rabbit anti-p38 antibody (Santa Cruz
Biotechnology). The cell mass was harvested 72 hours
after infection when the expression level of p38 reached
its maximum.
Frozen cell paste from cells expressing the
(His)6-tagged p38 was thawed in 5 volumes of Buffer A (50
mM NaH2POQ pH 8.0, 200 mM NaCl, 2mM !3-Mercaptoethanol, 100
Glycerol and 0.2 mM PMSF). After mechanical disruption
of the cells in a microfluidizer, the lysate was
centrifuged at 30,000 x g for 30 minutes. The
supernatant was incubated batchwise for 3-5 hours at 4°C
with Talon'' (Clontech) metal affinity resin at a ratio of
1 ml of resin per 2-4 mgs of expected p38. The resin was
settled by centrifugation at 500 x g for 5 minutes and
gently washed batchwise with Buffer A. The resin was
slurried and poured into a column (approx. 2.6 x 5.0 cm)
and washed with Buffer A + 5 mM imidazole.
The (His)6-p38 was eluted with Buffer A + 100
mM imidazole and subsequently dialyzed overnight at 4°C
against 2 liters of Buffer B, (50 mM HEPES, pH 7.5, 25 mM
I3-glycerophosphate, 5o glycerol, 2mM DTT). The His6 tag
was removed by addition of at 1.5 units thrombin
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-54-
(Calbiochem) per mg of p38 and incubation at 20°C for 2-3
hours. The thrombin was quenched by addition of 0.2 mM
PMSF and then the entire sample was loaded onto a 2 ml
benzamidine agarose (American Tnternational Chemical)
column.
The flow through fraction was directly loaded
onto a 2.6 x 5.0 cm Q-Sepharose (Pharmacia) column
previously equilibrated in Buffer B + 0.2 mM PMSF. The
p38 was eluted with a 20 column volume linear gradient to
0.6M NaCl in Buffer B. The eluted protein peak was
pooled and dialyzed overnight at 4°C vs. Buffer C (50 mM
HEPES pH 7.5, 5o glycerol, 50 mM NaCl, 2 mM DTT, 0.2 mM
PMSF) .
The dialyzed protein was concentrated in a
Centriprep (Amicon) to 3-4 ml and applied to a 2.6 x 100
cm Sephacryl S-100HR (Pharmacia) column. The protein was
eluted at a flow rate of 35 ml/hr. The main peak was
pooled, adjusted to 20 mM DTT, concentrated to 10-80
mgs/ml and frozen in aliquots at -70°C or used
immediately.
L'VTT?T)T L~ G
Activation of p38
p38 was activated by combining 0.5 mg/ml p38
with 0.005 mg/ml DD-double mutant MKK6 in Buffer B + lOmM
MgCl2, 2mM ATP, 0.2mM Na~V04 for 30 minutes at 20°C. The
activation mixture was then loaded onto a 1.0 x 10 cm
MonoQ column (Pharmacia) and eluted with a linear 20
column volume gradient to 1.0 M NaCl in Buffer B. The
activated p38 eluted after the ADP and ATP. The
activated p38 peak was pooled and dialyzed against buffer
B + 0.2mM Na~V09 to remove the NaCl. The dialyzed protein
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-55-
was adjusted to 1.1M potassium phosphate by addition of a
4.0M stock solution and loaded onto a 1.0 x l0 cm HIC
(Rainin Hydropore) column previously equilibrated in
Buffer D (10% glycerol, 20mM f3-glycerophosphate, 2.OmM
DTT) + 1.lMKaHPOq. The protein was eluted with a 20
column volume linear gradient to Buffer D + 50mM K2HP09.
The double phosphorylated p38 eluted as the main peak and
was pooled for dialysis against Buffer B + 0.2mM Na~V09.
The activated p38 was stored at -70°C.
'fTVTT/fT)T L~ 7
p38 Inhibition Assays
A. Inhibition of Phosphorylation of EGF Receptor
Peptide
This assay was carried out in the presence of
10 mM MgCl~, 25 mM I3-glycerophosphate, loo glycerol and
100 mM HEPES buffer at pH 7.6. For a typical ICSo
determination, a stock solution was prepared containing
all of the above components and activated p38 (5 nM).
The stock solution was aliquotted into vials. A fixed
volume of DMSO or inhibitor in DMSO (final concentration
of DMSO in reaction was 50) was introduced to each vial,
mixed and incubated for 15 minutes at room temperature.
EGF receptor peptide, KRELVEPLTPSGEAPNQALLR, a phosphoryl
acceptor in p38-catalyzed kinase reaction (1), was added
to each vial to a final concentration of 200 uM. The
kinase reaction was initiated with ATP (100 uM) and the
vials were incubated at 30°C. After 30 minutes, the
reactions were quenched with equal volume of 100
trifluoroacetic acid (TFA).
The phosphorylated peptide was quantified by
HPLC analysis. Separation of phosphorylated peptide from
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-56-
the unphosphorylated peptide was achieved on a reverse
phase column (Deltapak, 5 um, C18 100D, Part no. 011795)
with a binary gradient of water and acteonitrile, each
containing 0.1o TFA. IC5o (concentration of inhibitor
yielding 50o inhibition) was determined by plotting the
percent (o) activity remaining against inhibitor
concentration.
B. Inhibition of ATPase Activity
This assay is carried out in the presence of 10
mM MgCl~, 25 mM f3-glycerophosphate, 10o glycerol and 100
mM HEP.ES buffer at pH 7.6. For a typical Ki
determination, the Km for ATP in the ATPase activity of
activated p38 reaction is determined in the absence of
inhibitor and in the presence of two concentrations of
inhibitor. A stock solution is prepared containing all
of the above components and activated p38 (60 nM). The
stock solution is aliquotted into vials. A fixed volume
of DMSO or inhibitor in DMSO (final concentration of DMSO
in reaction was 2.50) is introduced to each vial, mixed
and incubated for 15 minutes at room temperature. The
reaction is initiated by adding various concentrations of
ATP and then incubated at 30°C. After 30 minutes, the
reactions are quenched with 50 u1 of EDTA (0.1 M, final
concentration), pH 8Ø The product of p38 ATPase
activity, ADP, is quantified by HPLC analysis.
Separation of ADP from ATP is achieved on a
reversed phase column (Supelcosil, LC-18, 3 um, part no.
5-8985) using a binary solvent gradient of following
composition: Solvent A - 0.1 M phosphate buffer
containing 8 mM tetrabutylammonium hydrogen sulfate
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-57-
(Sigma Chemical Co., catalogue no. T-7158), Solvent B -
Solvent A with 30o methanol.
Ki is determined from the rate data as a
function of inhibitor and ATP concentrations.
p38 inhibitors of this invention will inhibit
the ATPase activity of p38.
C. Inhibition of IZ-1, TNF, IL-6 and IL-8
Production in LPS-Stimulated PBMCs
Inhibitors were serially diluted in DMSO from a
mM stock. At least 6 serial dilutions were prepared.
Then 4x inhibitor stocks were prepared by adding 4 u1 of
an inhibitor dilution to 1 ml of RPMI1640 medium/l0o
15 fetal bovine serum. The 4x inhibitor stocks contained
inhibitor at concentrations of 80 ~zM, 32 ~M, 12.8 ~M,
5.12 ~.M, 2.048 ~M, 0.819 uM, 0.328 uM, 0.131 ~M, 0.052
~M, 0.021 uM etc. The 4x inhibitor stocks were pre-
warmed at 37°C until use.
20 Fresh human blood huffy cells were separated
from other cells in a Vacutainer CPT from Becton &
Dickinson (containing 4 ml blood and enough DPBS without
Mgr+/Ca2+ to fill the tube) by centrifugation at 1500 x g
for 15 min. Peripheral blood mononuclear cells (PBMCs),
located on top of the gradient in the Vacutainer, were
removed and washed twice with RPMI1640 medium/l0o fetal
bovine serum. PBMCs were collected by centrifugation at
500 x g for 10 min. The total cell number was determined
using a Neubauer Cell Chamber and the cells were adjusted
to a concentration of 4.8 x 106 cells/ml in cell culture
medium (RPMI1640 supplemented with loo fetal bovine
serum) .
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-58-
Alternatively, whole blood containing an anti-
coagulant was used directly in the assay.
100 ~.1 of cell suspension or whole blood were
placed in each well of a 96-well cell culture plate.
Then 50 p1 of the 4x inhibitor stock was added to the
cells. Finally, 50 u1 of a lipopolysaccharide (LPS)
working stock solution (16 ng/ml in cell culture medium)
was added to give a final concentration of 4 ng/ml LPS in
the assay. The total assay volume of the vehicle control
was also adjusted to 200 u1 by adding 50 u1 cell culture
medium. The PBMC cells or whole blood were then
incubated overnight (for 12-15 hours) at 37° C/5o C02 in a
humidified atmosphere.
The next day the cells were mixed on a shaker
for 3-5 minutes before centrifugation at 500 x g for 5
minutes. Cell culture supernatants were harvested and
analyzed by ELISA for levels of IL-1~i (R & D Systems,
Quantikine kits, #DBL50), TNF-oc (BioSource, #KHC3012),
IL-6 (Endogen, #EH2-IL6) and IL-8 (Endogen, #EH2-IL8)
according to the instructions of the manufacturer. The
ELISA data were used to generate dose-response curves
from which IC50 values were derived.
Results for the kinase assay ("kinase";
subsection A, above), IL-1, and TNF in LPS-stimulated
PBMC's ("cell") and IL-1, TNF, and IL-6 in whole blood
("WB") for various p38 inhibitors of this invention are
shown in Table 7 below:
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-59-
m W, 't o
CompoundM.W. KinaseCell Cell WB IL-1 WB TNF WB IL-6
IC50 IL-1 TNF IC50 IC50 IC50
(uM) IC50 IC50 (uM) (uM) (uM)
(uM) (uM)
13 559.55 0.031 0.012 0.022 0.140 0.055 0.083
9 489.43 1.0 0.05 0.05 12.2 20.0 11.0
544.51 5.0 2.2 4.3 0.8
Other p38 inhibitors of this invention will
also inhibit phosphorylation of EGF receptor peptide, and
5 will inhibit the production of IL-1, TNF and IL-6, as
well as IL-8, in LPS-stimulated PBMCs or in whole blood.
D. Inhibition of IL-~ and IL-8
Production in IL-1-Stimulated PBMCs
This assay is carried out on PBMCs exactly the
10 same as above except that 50 ~1 of an IL-1b working stock
solution (2 ng/ml in cell culture medium) is added to the
assay instead of the (LPS) working stock solution.
Cell culture supernatants are harvested as
described above and analyzed by ELISA for levels of IL-6
(Endogen, #EH2-IL6) and IL-8 (Endogen, #EH2-IL8)
according to the instructions of the manufacturer. The
ELISA data are used to generate dose-response curves from
which IC50 values were derived.
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-60-
E. Inhibition of LPS-Induced
Prostaglandin Endoperoxide Synthase-2
(PGHS-2, or COX-2) Induction in PBMCs
Human peripheral mononuclear cells (PBMCs) are
isolated from fresh human blood buffy coats by
centrifugation in a Vacutainer CPT (Becton & Dickinson).
x 106 cells are seeded in a 6-well tissue culture dish
containing RPMI 1640 supplemented with 10o fetal bovine
serum, 50U/ml penicillin, 50 ~g/ml streptomycin, and 2 mM
10 L-glutamine. Compounds are added at 0.2, 2.0 and 20 ~.tM
final concentrations in DMSO. LPS is then added at a
final concentration of 4 ng/ml to induce enzyme
expression. The final culture volume is 10 ml/well.
After overnight incubation at 37°C, 5o C02, the
15 cells are harvested by scraping and subsequent
centrifugation, the supernatant is removed, and the cells
are washed twice in ice-cold DPBS (Dulbecco's phosphate
buffered saline, BioWhittaker). The cells are lysed on
ice for 10 min in 50 u1 cold lysis buffer (20 mM Tris-
HC1, pH 7.2, 150 mM NaCl, 1o Triton-X-100, 1o deoxycholic
acid, 0. 1 o SDS, 1 mM EDTA, 2 o aprotinin (Sigma) , 10 ~g/ml
pepstatin, 10 ug/ml leupeptin, 2 mM PMSF, 1 mM
benzamidine, 1 mM DTT) containing 1 u1 Benzonase (DNAse
from Merck). The protein concentration of each sample is
determined using the BCA assay (Pierce) and bovine serum
albumin as a standard. Then the protein concentration of
each sample is adjusted to 1 mg/ml with cold lysis
buffer. To 100 u1 lysate an equal volume of 2xSDS PAGE
loading buffer is added and the sample is boiled for 5
min. Proteins (30 ug/lane) are size-fractionated on 4-
20o SDS PAGE gradient gels (Novex) and subsequently
transferred onto nitrocellulose membrane by
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
'~.'t~i:.'~ ~'iGz:, ~~ ~.7~. ~ ~. e"1~3 ~ "~ "~'~" ~ ~~ '~~' :''~'~. ?
~'#~~'~" ~ ~"~' ~ '~.s""' L~ ~;..%'~ ~, t~
~.z~ ~ ~ ~~~~~~ ~~ ~~. ,~ ~t~ ~~~.
~~~~c~~ ~~~ ~~~~
r~~~.~.~~~z~ :~
~~.~ar~
~~ ~ ~ :~c~'~~~:~.~~~
f ~.~~~~. ~~~~~r~.~a~ ~~c~r~~~ ~~.
~.~c~~ ~~~~~~~ ~~ ~.~~~~~ ?~~.~ ~~~~~h~
CA 02418389 2003-02-04
WO 02/14281 PCT/USO1/25015
-62-
by the addition of loo TCA containing 200 mM ATP. The
quenched reaction is harvested onto GF/C glass fiber
filter plates (Packard, Meriden, CT) using a Tomtec 9600
cell harvester (Tomtec, Hamden, CT). The plates are
washed with 5o TCA containing 1 mM ATP and water. 50 u1
of scintillation fluid is added to the plates, which are
then counted using a Packard scintillation counter
(Packard, Meriden, CT). IC50 values for inhibitory
compounds were determined using the same assay at a
series of compound concentrations.
While we have hereinbefore presented a number
of embodiments of this invention, it is apparent that our
basic construction can be altered to provide other
embodiments which utilize the methods of this invention.
25
